Crinetics Pharmaceuticals, Inc. (CRNX) Downgraded to Neutral by UBS

Market Context

Crinetics Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $83.86 with a market capitalization of $4.7B.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow UBS's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Crinetics Pharmaceuticals, Inc.

Among the 10 most recent ratings: 2 Buy, 8 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 28, 2026	UBS	Neutral	N/A
Jul 08, 2026	TD Cowen	Hold	N/A
Jul 08, 2026	Evercore ISI Group	In-Line	N/A
Jul 07, 2026	Jefferies	Hold	N/A
Jul 07, 2026	Jones Trading	Hold	N/A

Related Tools: Analyst Ratings Dashboard | View CRNX Stock Page